Cargando…
P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012125/ http://dx.doi.org/10.1097/01.HS9.0000829588.31575.a9 |
| _version_ | 1784687736636047360 |
|---|---|
| author | Sonneveld, P Chanan-Khan, A Weisel, K Nooka, AK Masszi, T Beksac, M Spicka, I Hungria, V Munder, M Mateos, MV Mark, TM Levin, MD Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Spencer, A |
| author_facet | Sonneveld, P Chanan-Khan, A Weisel, K Nooka, AK Masszi, T Beksac, M Spicka, I Hungria, V Munder, M Mateos, MV Mark, TM Levin, MD Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Spencer, A |
| author_sort | Sonneveld, P |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9012125 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90121252022-04-18 P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL Sonneveld, P Chanan-Khan, A Weisel, K Nooka, AK Masszi, T Beksac, M Spicka, I Hungria, V Munder, M Mateos, MV Mark, TM Levin, MD Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Spencer, A Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9012125/ http://dx.doi.org/10.1097/01.HS9.0000829588.31575.a9 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Poster Sonneveld, P Chanan-Khan, A Weisel, K Nooka, AK Masszi, T Beksac, M Spicka, I Hungria, V Munder, M Mateos, MV Mark, TM Levin, MD Ahmadi, T Qin, X Garvin Mayo, W Gai, X Carey, J Carson, R Spencer, A P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_full | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_fullStr | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_full_unstemmed | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_short | P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL |
| title_sort | p04: daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with previously treated multiple myeloma: overall survival results from the phase 3 castor trial |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012125/ http://dx.doi.org/10.1097/01.HS9.0000829588.31575.a9 |
| work_keys_str_mv | AT sonneveldp p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT chanankhana p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT weiselk p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT nookaak p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT masszit p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT beksacm p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT spickai p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT hungriav p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT munderm p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT mateosmv p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT marktm p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT levinmd p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT ahmadit p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT qinx p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT garvinmayow p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT gaix p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT careyj p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT carsonr p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial AT spencera p04daratumumabplusbortezomibanddexamethasoneversusbortezomibanddexamethasonealoneinpatientswithpreviouslytreatedmultiplemyelomaoverallsurvivalresultsfromthephase3castortrial |